Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Website: cyclerion.com



Growth: Good revenue growth rate 100.0%, there is acceleration compared to average historical growth rates 45.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 533.3%. On average the margin is decreasing steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 50% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -626.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 110.3% higher than minimum and 87.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -70.0x by EV / Sales multiple

Key Financials (Download financials)

Ticker: CYCN
Share price, USD:  (-5.3%)2.86
year average price 2.95  


year start price 3.12 2024-07-27

min close price 1.36 2024-11-26

max close price 6.35 2024-12-04

current price 2.86 2025-07-26
Common stocks: 2 176 050

Dividend Yield:  0.0%
EV / Sales: -4.6x
Margin (EBITDA LTM / Revenue): -1 533.3%
Fundamental value created in LTM:
Market Cap ($m): 6
Net Debt ($m): -20
EV (Enterprise Value): -14
Price to Book: 0.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-12-17globenewswire.com

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

2024-08-07globenewswire.com

Regina Graul, Ph.D., Promoted to Chief Executive Officer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-07 2024-05-07 2024-03-05 2023-11-13 2023-07-28 2023-05-12 2023-03-22 2022-11-03
acceptedDate 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 194 000 0 0 0 0 0 0 2M 0
costOfRevenue 0 0 0 0 0 0 0 0 0
grossProfit 194 000 0 0 0 0 0 0 2M 0
grossProfitRatio 1 0 0 0 0 0 0 1 0
researchAndDevelopmentExpenses 81 000 105 000 44 000 24 000 580 000 886 000 4M 4M 7M
generalAndAdministrativeExpenses 1M 1M 2M 2M 2M 3M 3M 4M 4M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1M 1M 2M 2M 2M 3M 3M 4M 4M
otherExpenses 0 0 0 0 0 0 0 -608 000 0
operatingExpenses 1M 1M 2M 2M 3M 4M 7M 7M 11M
costAndExpenses 1M 1M 2M 2M 3M 4M 7M 7M 11M
interestIncome 42 000 62 000 76 000 101 000 107 000 62 000 0 0 0
interestExpense 0 0 0 -88 000 0 0 88 000 183 000 111 000
depreciationAndAmortization 0 0 43 276 43 812 7M 0 0 -389 000 0
ebitda -1M -1M -2M -2M 593 000 -4M -7M -7M -11M
ebitdaratio -5.814 0 0 0 0 0 0 -4.522 0
operatingIncome -1M -1M -2M -2M -6M -4M -7M -7M -11M
operatingIncomeRatio -5.814 0 0 0 0 0 0 -4.522 0
totalOtherIncomeExpensesNet 405 000 62 000 76 000 101 000 -3M 62 000 88 000 132 000 111 000
incomeBeforeTax -723 000 -1M -2M -2M -6M -4M -7M -7M -10M
incomeBeforeTaxRatio -3.727 0 0 0 0 0 0 -4.441 0
incomeTaxExpense 0 0 -43 276 17M -17M 0 -176 000 -183 000 -222 000
netIncome -723 000 -1M -2M -2M 8M -4M -7M -7M -10M
netIncomeRatio -3.727 0 0 0 0 0 0 -4.328 0
eps -0.29 -0.53 -0.62 -0.68 -3.36 -1.83 -3.11 -0.23 -0.24
epsdiluted -0.29 -0.53 -0.62 -0.68 -3.36 -1.83 -3.11 -0.23 -0.24
weightedAverageShsOut 3M 3M 2M 2M 2M 2M 2M 30M 43M
weightedAverageShsOutDil 3M 3M 2M 2M 2M 2M 2M 30M 43M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-07 2024-05-07 2024-03-05 2023-11-13 2023-07-28 2023-05-12 2023-03-22 2022-11-03
acceptedDate 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 3M 5M 6M 8M 9M 6M 7M 13M 20M
shortTermInvestments 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 3M 5M 6M 8M 9M 6M 7M 13M 20M
netReceivables 44 000 0 0 0 0 0 96 000 96 000 227 000
inventory 0 0 0 0 0 0 567 000 805 000 0
otherCurrentAssets 632 000 127 000 318 000 11 000 30 000 428 000 503 000 537 000 488 000
totalCurrentAssets 4M 5M 6M 8M 10M 7M 8M 15M 22M
propertyPlantEquipmentNet 0 0 0 0 0 1M 1M 1M 1M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 5M 5M 5M 5M 5M 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 0 2M 2M 2M 2M
totalNonCurrentAssets 5M 5M 5M 5M 5M 3M 3M 3M 3M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 9M 10M 11M 13M 15M 10M 11M 18M 25M
accountPayables 304 000 651 000 741 000 1M 814 000 2M 4M 3M 2M
shortTermDebt 0 0 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 396 000 631 000 700 000 888 000 2M 3M 4M 5M 7M
totalCurrentLiabilities 700 000 1M 1M 2M 2M 5M 8M 8M 9M
longTermDebt 0 0 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 4M 3M -2M
totalNonCurrentLiabilities 0 0 0 0 0 0 4M 3M 2M
otherLiabilities 0 0 0 0 0 0 -4M -3M -2M
capitalLeaseObligations 0 0 0 0 0 0 0 0 0
totalLiabilities 700 000 1M 1M 2M 2M 5M 8M 8M 9M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0
retainedEarnings -268M -267M -266M -264M -263M -270M -266M -259M -252M
accumulatedOtherComprehensiveIncomeLoss 0 0 -16 000 -12 000 -18 000 -16 000 -19 000 -20 000 -28 000
othertotalStockholdersEquity 276M 276M 276M 276M 276M 275M 270M 270M 268M
totalStockholdersEquity 8M 9M 10M 11M 13M 5M 4M 10M 17M
totalEquity 8M 9M 10M 11M 13M 5M 4M 10M 17M
totalLiabilitiesAndStockholdersEquity 9M 10M 11M 13M 15M 10M 11M 18M 25M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 9M 10M 11M 13M 15M 10M 11M 18M 25M
totalInvestments 5M 5M 5M 5M 5M 0 0 0 0
totalDebt 0 0 0 0 0 0 0 0 0
netDebt -3M -5M -6M -8M -9M -6M -7M -13M -20M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-07 2024-05-07 2024-03-05 2023-11-13 2023-07-28 2023-05-12 2023-03-22 2022-11-03
acceptedDate 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -723 000 -1M -2M -2M 8M -4M -7M -7M -10M
depreciationAndAmortization 0 0 0 0 0 0 0 65 000 0
deferredIncomeTax 0 0 0 0 0 0 0 0 0
stockBasedCompensation 138 000 184 000 181 000 103 000 159 000 379 000 426 000 1M 2M
changeInWorkingCapital 478 000 32 000 -510 000 50 000 -2M -3M 314 000 -951 000 -1M
accountsReceivables -44 000 0 0 0 0 96 000 0 131 000 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 184 000 -91 000 -456 000 385 000 -1M -2M 955 000 1M -1M
otherWorkingCapital 338 000 123 000 -54 000 -335 000 -1M -788 000 -641 000 -2M 41 000
otherNonCashItems -2M 0 637 000 -282 000 -12M 0 0 -65 000 0
netCashProvidedByOperatingActivities -2M -1M -2M -2M -7M -7M -6M -7M -10M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 -10M 10M 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 -10M 10M 0 0 0 0
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 0 -5M 0 5M 0 29 000 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 5M 0 0 0 -17 000 0
netCashUsedProvidedByFinancingActivities 0 0 0 0 0 5M 0 12 000 0
effectOfForexChangesOnCash 0 -2000 -4000 4000 0 3000 1000 8000 -3000
netChangeInCash -2M -1M -2M -2M 3M -2M -6M -7M -10M
cashAtEndOfPeriod 3M 5M 6M 8M 9M 6M 7M 13M 20M
cashAtBeginningOfPeriod 5M 6M 8M 9M 6M 7M 13M 20M 30M
operatingCashFlow -2M -1M -2M -2M -7M -7M -6M -7M -10M
capitalExpenditure 0 0 0 0 0 0 0 0 0
freeCashFlow -2M -1M -2M -2M -7M -7M -6M -7M -10M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2023-12-04 13:00 ET
Cyclerion Appoints Regina Graul, Ph.D., as President
2023-11-30 23:16 ET
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
2023-07-31 11:00 ET
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
2023-06-01 20:00 ET
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-05-15 17:00 ET
Cyclerion Announces Reverse Stock Split
2023-05-11 22:00 ET
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
2023-05-11 22:00 ET
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
2023-04-03 11:30 ET
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
2023-03-27 11:00 ET
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
2023-03-22 20:40 ET
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
2022-11-22 12:00 ET
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
2022-10-06 12:00 ET
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
2022-08-09 20:00 ET
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
2022-07-28 11:00 ET
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
2022-07-26 11:00 ET
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
2022-06-28 13:00 ET
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
2022-06-22 12:30 ET
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
2022-06-17 12:00 ET
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
2022-06-10 11:00 ET
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
2022-06-06 11:00 ET
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
2022-05-04 20:01 ET
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
2022-02-24 21:01 ET
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
2022-02-23 13:00 ET
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
2022-01-26 13:00 ET
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
2021-11-11 22:32 ET
Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference
2021-11-09 21:01 ET
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
2021-09-22 12:00 ET
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
2021-09-08 12:00 ET
Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
2021-08-23 21:00 ET
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
2021-07-29 21:00 ET
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
2021-07-22 20:30 ET
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
2021-07-08 23:22 ET
Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership
2021-07-08 20:30 ET
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
2021-06-04 12:00 ET
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
2021-06-04 12:00 ET
Cyclerion Therapeutics Announces $18 Million Private Placement
2021-05-27 20:30 ET
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
2021-05-25 11:00 ET
Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
2021-04-27 13:00 ET
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
2021-04-26 11:00 ET
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
2021-04-21 11:30 ET
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
2021-04-20 11:00 ET
Cyclerion Therapeutics to Host Pipeline Update Webinar
2021-03-30 11:00 ET
AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer
2021-03-24 20:05 ET
TransMedics Appoints Stephanie Lovell to Board of Directors
2021-03-18 21:00 ET
Cyclerion Therapeutics Announces Departure of Chief Medical Officer
2021-02-25 12:00 ET
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
2021-01-25 12:00 ET
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
2021-01-04 12:00 ET
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
2020-12-21 12:30 ET
Cyclerion Announces Leadership Transitions
2020-11-05 12:00 ET
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
2020-10-14 11:00 ET
Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
2020-10-14 11:00 ET
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
2020-09-04 11:00 ET
Cyclerion to Participate at Upcoming September 2020 Investor Conferences
2020-08-25 11:00 ET
Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
2020-08-03 13:25 ET
Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
2020-07-30 13:00 ET
Cyclerion Therapeutics Completes $24 Million Private Placement
2020-07-17 11:00 ET
Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit
2020-06-18 20:01 ET
Cyclerion to Host Webcast Investor Event on July 9, 2020
2020-04-10 11:00 ET
Cyclerion Updates Corporate Progress
2020-01-13 12:00 ET
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
2019-12-23 12:00 ET
Cyclerion to Present at the J.P. Morgan Healthcare Conference
2019-11-27 12:00 ET
Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
2019-10-30 11:31 ET
Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
2019-10-30 11:30 ET
Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
2019-10-08 12:00 ET
Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings
2019-09-10 12:00 ET
Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17

SEC forms

Show financial reports only

SEC form 8
2025-06-18 20:41 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 10
2025-05-06 20:15 ET
Cyclerion Therapeutics reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Cyclerion Therapeutics reported for 2025 q1
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 10
2025-03-04 21:15 ET
Cyclerion Therapeutics reported for 2024 q4
SEC form 10
2025-03-04 00:00 ET
Cyclerion Therapeutics reported for 2024 q4
SEC form 10
2024-11-14 16:30 ET
Cyclerion Therapeutics reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Cyclerion Therapeutics reported for 2024 q3
SEC form 10
2024-08-07 00:00 ET
Cyclerion Therapeutics reported for 2024 q2
SEC form 10
2024-05-07 00:00 ET
Cyclerion Therapeutics reported for 2024 q1
SEC form 10
2024-03-05 00:00 ET
Cyclerion Therapeutics reported for 2023 q4
SEC form 10
2023-11-13 00:00 ET
Cyclerion Therapeutics reported for 2023 q3
SEC form 10
2023-07-28 16:48 ET
Cyclerion Therapeutics reported for 2023 q2
SEC form 10
2023-07-28 00:00 ET
Cyclerion Therapeutics reported for 2023 q2
SEC form 6
2023-07-19 17:27 ET
Cyclerion Therapeutics published news for 2023 q2
SEC form 6
2023-07-12 16:12 ET
Cyclerion Therapeutics published news for 2023 q2
SEC form 6
2023-06-27 16:53 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 17:23 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 19:37 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 19:26 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-04-03 16:32 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-04-03 09:53 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-03-22 17:00 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 10
2023-03-22 16:55 ET
Cyclerion Therapeutics reported for 2022 q4
SEC form 6
2023-03-22 16:52 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 10
2023-03-22 00:00 ET
Cyclerion Therapeutics reported for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 6
2022-11-29 16:00 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 6
2022-11-22 16:31 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 17:00 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Cyclerion Therapeutics reported for 2022 q3
SEC form 6
2022-10-06 08:01 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 6
2022-09-30 17:15 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 16:04 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 16:01 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Cyclerion Therapeutics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-28 09:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-26 16:30 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-26 07:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-06-15 16:03 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 07:01 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-06-03 16:00 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:07 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-05-04 16:01 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Cyclerion Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-04-26 07:52 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-02-24 16:06 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 16:01 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 6
2021-12-10 16:32 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:31 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:31 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 16:01 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 16:01 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-10-28 16:50 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-09-30 09:01 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:40 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:37 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:31 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-19 16:51 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 16:58 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-07-29 16:54 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-06-28 17:27 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:25 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:22 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:17 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:14 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:11 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:05 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-25 16:31 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-04 16:37 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-19 18:16 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 21:27 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 16:39 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 10
2021-04-30 16:04 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 07:01 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-27 09:20 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-26 08:58 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-03-19 06:01 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-03-18 17:00 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 07:35 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 07:31 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 17:49 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 17:45 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2020-12-30 21:53 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-12-21 16:35 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 07:00 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-10-14 07:22 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-10-01 07:21 ET
Cyclerion Therapeutics published news for 2020 q3